• 1. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

Research Briefing on 3-(1-ethyl-1H-pyrazol-4-yl)-2,2-dimethylpropan-1-ol (CAS: 1493079-12-1) in Chemical Biology and Pharmaceutical Applications

Recent advancements in chemical biology and pharmaceutical research have highlighted the significance of small-molecule compounds, such as 3-(1-ethyl-1H-pyrazol-4-yl)-2,2-dimethylpropan-1-ol (CAS: 1493079-12-1), in drug discovery and therapeutic development. This compound, characterized by its pyrazole core and dimethylpropanol side chain, has emerged as a promising scaffold due to its unique physicochemical properties and potential biological activities. This briefing synthesizes the latest findings on its synthesis, mechanism of action, and applications in medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry explored the synthetic pathways for 3-(1-ethyl-1H-pyrazol-4-yl)-2,2-dimethylpropan-1-ol, emphasizing its scalability and purity optimization. Researchers employed a multi-step protocol involving palladium-catalyzed cross-coupling reactions to introduce the pyrazole moiety, followed by Grignard addition to achieve the dimethylpropanol side chain. The study reported a 78% overall yield with >99% HPLC purity, making it a viable candidate for industrial-scale production.

In pharmacological investigations, this compound demonstrated selective modulation of G protein-coupled receptors (GPCRs), particularly the adenosine A_2A receptor, as detailed in a 2024 Nature Chemical Biology paper. Molecular docking simulations revealed that the pyrazole group forms critical hydrogen bonds with Thr88 and Asn181 residues, while the dimethylpropanol side chain enhances membrane permeability (logP = 2.3). In vitro assays showed an IC₅₀ of 120 nM for A_2A antagonism, suggesting potential applications in neurodegenerative diseases.

Further preclinical studies highlighted its utility as a bifunctional linker in PROTAC (Proteolysis Targeting Chimera) design. A team at Scripps Research Institute (2024) conjugated 1493079-12-1 to E3 ligase ligands, resulting in compounds with improved degradation efficiency (DC₅₀ < 50 nM for BRD4). The dimethylpropanol moiety was found to stabilize ternary complex formation, as evidenced by cryo-EM structural analysis.

Ongoing clinical-stage research (Phase I/II trials) by Vertex Pharmaceuticals investigates derivatives of 1493079-12-1 as CFTR potentiators for cystic fibrosis. Early data indicate a 40% improvement in chloride transport at 10 μM concentration, with favorable ADME profiles (t_1/2 = 8.2 h in human hepatocytes). Structural analogs are also being evaluated for anti-inflammatory properties through NLRP3 inflammasome inhibition.

In conclusion, 3-(1-ethyl-1H-pyrazol-4-yl)-2,2-dimethylpropan-1-ol represents a versatile chemical entity with broad therapeutic potential. Future directions include optimization of its pharmacokinetic properties and exploration of novel target engagements, particularly in immuno-oncology and CNS disorders. Collaborative efforts between academia and industry are expected to accelerate its translation into clinical applications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)